1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote Korea Stock Exchange  -  2022-06-26
806000.00 KRW   -3.01%
06:11aSouth Korean Stocks Rise for Second Day as Investors Speculate Fed Rate Hike Pace; Samsung Bio Stock Falls 3%
MT
03:14aSouth Korea's Corporate Direct Financing Declines 3.5% in May
MT
05/25South Korea Indexes Close Higher on Gains by Chem, Bio Firms; Samsung Biologics Adds 3%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/16/2022 | 03:55am EDT

Samsung Biologics Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 43,029.2 million compared to KRW 27,589.04 million a year ago. Net income was KRW 146,942.73 million compared to KRW 60,975.54 million a year ago. Basic earnings per share from continuing operations was KRW 2,221 compared to KRW 922 a year ago. Diluted earnings per share from continuing operations was KRW 2,218. Basic earnings per share was KRW 2,221 compared to KRW 922 a year ago. Diluted earnings per share was KRW 2,218.


ę S&P Capital IQ 2022
All news about SAMSUNG BIOLOGICS CO.,LTD.
06:11aSouth Korean Stocks Rise for Second Day as Investors Speculate Fed Rate Hike Pace; Sams..
MT
03:14aSouth Korea's Corporate Direct Financing Declines 3.5% in May
MT
05/25South Korea Indexes Close Higher on Gains by Chem, Bio Firms; Samsung Biologics Adds 3%
MT
05/25South Korean Stocks Close Higher on Chemical, Bio Stocks’ Gains
MT
05/24Samsung Electronics Lays Out Five-Year Plan with $355 Billion Investment in Chips, Biop..
MT
05/23SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
05/16Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 3..
CI
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2022 1 991 B 1,55 B 1,55 B
Net income 2022 542 B 0,42 B 0,42 B
Net Debt 2022 566 B 0,44 B 0,44 B
P/E ratio 2022 102x
Yield 2022 -
Capitalization 57 366 B 44 668 M 44 668 M
EV / Sales 2022 29,1x
EV / Sales 2023 25,5x
Nbr of Employees 2 886
Free-Float 25,6%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 806 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Doyoung Heo Head-Finance & Vice President
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-10.74%45 825
CSL LIMITED-6.70%90 814
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 498
BIOGEN INC.-11.67%31 038
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-12.56%24 084
UCB-19.34%16 152